Drugs / L. reuteri RC-14
last change Dec 2007 re-read 3 minutes ago

L. reuteri RC-14

Other / unclassified

Developed for
vulvovaginal candidiasis
Investigated by
Chr Hansen · Faith Mediplex · UrexBiotech

Trials 1

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00479947 May → Dec 2007 vulvovaginal candidiasis Faith Mediplex Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as L. reuteri RC-14 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479947 ↗
Modality Other / unclassified “two well documented strains of lactobacilli” NCT00479947 ↗
Route Oral “one oral dose of Fluconazole + capsules of L. rhamnosus GR-1 and L reuteri RC-14 containing 5 billion live organisms for 3 months” NCT00479947 ↗